Harrow Q2 2024 record revenue $48.9M (+46% YoY); adj EBITDA $8.8M; guides FY rev >$180M

HARROW, INC.

2024-Q2 EPS reported -$0.56 revenue$83,526,000

Record Q2 revenue $48.9M, up 46% YoY and 42% sequentially; GAAP net loss $(6.5)M.
Adjusted EBITDA $8.8M; core gross margin 79% (up from 78%).
IHEEZO unit demand up 98% QoQ; VEVYE prescriptions up 212% QoQ; new IHEEZO supply agreements.
FY2024 revenue guidance >$180M (excluding TRIESENCE); expects back-half outperformance.
TRIESENCE PPQ Batch 2 passes initial tests; third batch scheduled; potential 2024 relaunch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.